SavedAdd your journal

Journals / Ortadoğu Tıp Dergisi / 2018 / Cilt: 10 - Sayı: 3

Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment

Tip 2 diyabet tedavisinde sodyum-glukoz ko-transporter 2 inhibitörleri

İrfan KARAHAN
Çağar ALP
Aşkın GÜNGÜNEŞ
Pages
381–385
Publication Date
2018-09-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Drug management and adverse effects were reviewed in this text.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are new agents which are used in diabetes treatment.
📊
Key Findings & Data:Mechanism of action is inhibiting of glucose reabsorbation and increasing of urinary glucose excretion from renal proximal tubules.
💡
Conclusion & Impact:Drug management and adverse effects were reviewed in this text.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:SGLT-2 inhibitörleri · tip 2 diyabet · SGLT-2 inhibitors

Abstract

Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are new agents which are used in diabetes treatment. Mechanism of action is inhibiting of glucose reabsorbation and increasing of urinary glucose excretion from renal proximal tubules. These agents could improve blood pressure and weight gain disorders. Many studies showed some of these agents’ benefits on cardiovascular system. Main adverse effects are infections. Drug management and adverse effects were reviewed in this text.

Özet

Sodyum-glukoz ko-transporter 2 (SGLT-2) inhibitörleri, diyabet tedavisinde yeni kullanmaya başlanılan ajanlardır. Temel etki mekanizması proksimal renal tübülden glukoz reabsorbsiyonunu engelleyerek üriner glukoz ekskresyonunu arttırmaktır. Kan basıncı ve vücut ağırlığı üzerine olumlu etkileri gösterilmiştir. Bunun dışında bazı çalışmalarda kardiyovasküler faydaları da olabileceği gösterilmiştir. Başlıca yan etkileri enfeksiyonlar olup diğer yan etkiler ve ilaç yönetimi bu yazıda tartışılmıştır.

🔖

Cite This Article

KARAHAN, İ., ALP, Ç., GÜNGÜNEŞ, A. (2018). Sodium-glucose co-transporter-2 inhibitors in Type 2 diabetes treatment. Ortadoğu Tıp Dergisi, Cilt: 10 - Sayı: 3, 381–385. https://ajindex.com/articles/88459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Singh SK, Gupta A: SGLT2 inhibitors for treatment of type 2 diabetes mellitus: Focus on canagliflozin. Muller Journal of Medical Sciences and Research 2014;5:166
  2. Balfour PC, Rodriguez CJ, Ferdinand KC: Blood pressure and cardiovascular effects of new and emerging antidiabetic agents. Current hypertension reports 2014;16:455
  3. Liakos A, Karagiannis T, Athanasiadou E et al: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 2014, 16:984-93
  4. Clar C, Gill JA, Waugh N: Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ open 2012;2:e001007
  5. Zaccardi F, Webb D, Htike Z, Youssef D, Khunti K, Davies M: Efficacy and safety of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes mellitus: systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism 2016;18:783-94
  6. Zinman B, Wanner C, Lachin JM et al: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine 2015;373:2117-128
  7. Neal B, Perkovic V, Mahaffey KW et al: Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine 2017
  8. Wanner C, Inzucchi SE, Lachin JM et al: Empagliflozin and progression of kidney disease in type 2 diabetes. New England Journal of Medicine 2016;375:323-34. 9. Škrtić M, Yang GK, Perkins BA et al: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 2014;57:2599-602
  9. Liu X-Y, Zhang N, Chen R, Zhao J-G, Yu P: Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. Journal of diabetes and its complications 2015;29:1295-303
  10. Inagaki N, Kondo K, Yoshinari T, Kuki H: Efficacy and safety of canagliflozin alone or as add‐on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: A 52‐week open‐label study. Journal of diabetes investigation 2015;6:210-8
  11. Nauck MA: Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug design, development and therapy 2014;8:1335
  12. Inzucchi SE, Zinman B, Wanner C et al: SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabetes and Vascular Disease Research 2015;12:90-100
  13. Musso G, Gambino R, Cassader